INTRODUCTION
Malignant progression promotes the selection of less immunogenic tumor variants (Vesely and Schreiber, 2013) . However, clinical evidence supports that T cells exert immune pressure against the progression of even advanced cancers (Fridman et al., 2011; Zhang et al., 2003) . In addition, de novo elicitation or reactivation of protective immunity is required for the effectiveness of several conventional or targeted anticancer therapies (Zitvogel et al., 2013) . Still, established tumors are not spontaneously rejected by the immune system. Even when tumor cells remain immunogenic, the effector activity of tumor-reactive lymphocytes is weakened during malignant progression . In tumor-bearing hosts, two key mechanisms mediated by different transcriptional pathways (Crespo et al., 2013) render tumor-reactive lymphocytes unresponsive through defective T cell priming (anergy) (Zheng et al., 2012) or sustained exposure to suboptimal antigen concentrations (exhaustion) (Wherry, 2011) .
Besides inherent T cell unresponsiveness, tumor, vascular, stromal, and immune cells contribute to create an inflammatory and metabolically hostile environment where multiple immunosuppressive networks converge to abrogate residual T cell activity (Zou, 2005) . Expression of the inhibitory receptors PD-1, LAG-3, and CTLA-4 (Baitsch et al., 2012) in leukocytes and tumor cells also contributes to maintain T cell inactivity. In addition, Indoleamine 2,3-dioxygenase (IDO) and its tolerogenic metabolites, immunosuppressive cytokines, or nitrogen-reactive species all contribute to abrogate lingering lymphocyte activity in most solid tumors. Interestingly, some immunosuppressive pathways are more active in tumors infiltrated by activated T cells (Spranger et al., 2013) , suggesting that these patients could be superior beneficiaries of immunotherapies targeting immunosuppression. Indeed, emerging clinical evidence supports that blockade of tolerogenic pathways unleashes antitumor immunity, but only in some patients (Pardoll and Drake, 2012) . Understanding what is truly relevant for the abrogation of protective immunity in different cancers is needed for implementing more effective antitumor immunotherapies.
Transforming growth factor-b (TGF-b) is a lymphocyte inhibitor secreted by multiple cells and frequently overexpressed in aggressive cancers (Flavell et al., 2010; Wrzesinski et al., 2007) . Tumors induce dendritic cells (DCs) to secrete TGF-b, promoting regulatory T cell (Treg) expansion and indirect suppression of T cell effectors (Ghiringhelli et al., 2005; Hanks et al., 2013) . Conventional T cells also produce TGF-b. Interestingly, in some models, T cell-derived TGF-b (including TGF-b produced by Treg cells) is sufficient for antitumor T cell suppression, while ablation of TGF-b only in Treg cells has insignificant effects (Donkor et al., 2011) . Furthermore, TGF-b can also suppress effector cytokines in antitumor CD8 + lymphocytes (Ahmadzadeh and Rosenberg, 2005) . However, the pathways elicited by TGF-b signaling specifically in unresponsive tumorreactive T cells and their overall impact remain incompletely understood. TGF-b could inhibit T cell proliferation through Smad3 transcription factor-dependent repression of interleukin-2 (IL-2) (McKarns et al., 2004) and also through IL-2-independent mechanisms that involve Smad3 binding to the Myc promoter (Frederick et al., 2004) . Still, it is unknown whether these pathways play a major role in tumor-induced immunosuppression, or whether other tumor-induced factors influence TGF-b-signaling. Forkhead box (FOX) proteins are transcription factors with pleiotropic functions in the development and activity of immune cells. In naive T cells, constitutive expression of Foxp1 enforces quiescence by repressing the IL-7 receptor, implying that a cellintrinsic, Foxp1-dependent transcriptional program actively maintains naive lymphocytes ''at rest'' (Feng et al., 2011; Hamilton and Jameson, 2012) . Interestingly, Foxp1 is downregulated in exhausted (but not in memory) CD8 + lymphocytes in chronic viral infections (Doering et al., 2012) , but the functional relevance of this phenotype, or whether these patterns are recapitulated in antitumor T cells, remain completely unknown.
Here, we report that Foxp1 is universally upregulated in human and mouse tumor-infiltrating effector T cells. Foxp1 mediates TGF-b signaling by interacting with Smad proteins as an obligate transcriptional corepressor and is required for dampening antitumor immunity. Our results identify a hitherto unknown mechanism of tumor-induced effector T cell suppression involving T cell-intrinsic transcriptional changes different from anergy or exhaustion.
RESULTS
Tumor-Reactive T Cells Upregulate Foxp1 in the Tumor Microenvironment Foxp1 is downregulated in exhausted CD8 + T cells in chronic viral infections (Doering et al., 2012) . However, it has been shown to enforce quiescence in naive lymphocytes (Feng et al., 2011) , and its role in antitumor T cells remains to be determined. To define the expression of Foxp1 in human ovarian cancer-infiltrating lymphocytes, we used antibodies that detect two Foxp1 isoforms in mouse T cells: constitutively expressed Foxp1a, which maintains naive lymphocyte quiescence (Feng et al., 2011) , and inducible Foxp1d. Accordingly, we also identified two predominant bands of $80 and $66 kDa in human T cells, consistent with the size of Foxp1.1 (the >97% similar human ortholog of mouse Foxp1a) and the human counterpart of mouse Foxp1d, respectively ( Figure 1A ). Compared to activated (CD45RA À ) or naive (CD45RA + ) T cells from the blood of different healthy donors, CD8 + tumor-infiltrating lymphocytes (TILs) from six randomly selected patients overexpressed both Foxp1 isoforms, in both primary and metastatic ovarian tumors (Figures 1A and 1B; see Figure S1A available online). Foxp1 upregulation in ovarian cancer was independent of the exhaustion status of T cells, because two different Foxp1 variants were expressed at higher (although variable) amounts independently of PD-1 expression, the inhibitory receptor associated with exhaustion in one third of ovarian cancer CD8 + TILs (Duraiswamy et al., 2013 Figures 1C and 1D) . Importantly, Foxp1 overexpression was not caused by mere homing to solid tissues, because Foxp1 was higher in intratumoral lymphocytes than in T cells in matching tumor-free tissue from multiple patients ( Figure 1E ; Figure S1B ). In addition, Foxp1 overexpressing CD8 + lymphocytes harvested from ovarian tissue exhibited lower FSC (associated with smaller cell size), compared to their counterparts in peripheral blood from the same patient ( Figure 1F ). Because tumor-reactive T cells are contained in both PD-1 À and PD-1 + fractions of TILs (Matsuzaki et al., 2010) , we next sought to define how tumor antigen-specific T cells upregulate Foxp1 in the tumor microenvironment (TME). For that purpose, we activated mouse splenic T cells with DCs pulsed with immunogenic (UV-plus g-irradiated) ID8-Defb29-Vegf-a cancer cells, a system that results in aggressive and widely disseminated orthotopic ovarian tumors Cubillos-Ruiz et al., 2009) . As reported, $70% of de novo activated lymphocytes showed activation markers within 7 days Nesbeth et al., 2010 ) (data not shown). Notably, recently primed CD8 + T cells exhibited lower amounts of Foxp1a compared to naive T cells (data not shown), while both Foxp1a and Foxp1d (Feng et al., 2011) were upregulated in these cells in vivo in the TME within 3 days after adoptive transfer (Figure 1G) . Universal ovarian microenvironmental factors such as hypoxia, PGE2, or Estradiol Scarlett et al., 2012) had no measurable effect on Foxp1 upregulation in activated T cells (Figures S1C and S1D) . Incubation with tumor-derived regulatory DCs or myeloid-derived suppressor cells (MDSCs) also had negligible effects on the expression of any Foxp1 isoform ( Figure S1D ). In our hands, IL-6, IL-2, IL-23, IL-17, IL-15, IL-7, or vascular endothelial growth factor-a (Vegfa) also did not affect Foxp1 amounts in activated T cells (Figure S1E) . In contrast, signaling through the integrin ligand ICAM-1, the chemokine CXCL12 and, to a lesser extent, TGF-b, induced a modest but reproducible upregulation of Foxp1, which was enhanced in an additive manner ( Figure S1F (Figure 2A ; Figure S2A ).
When equal numbers of Foxp1-deficient and control tumorreactive T cells were adoptively transferred into congenic tumor-bearing mice, the proportions and absolute numbers of CD8 + T cells lacking Foxp1 were $4-fold increased ( tumor antigen-primed Foxp1-deficient, but not control CD8 + T cells selectively proliferated in the TME for at least 8 days (Figure 2C ; Figure S2B ). Foxp1 overexpressing T cells did not undergo death, but remained unresponsive at tumor beds (Figures 2C and 2D; . Importantly, selective expansion of Foxp1-deficient T cells was driven by response to cognate (tumor) antigen, because Foxp1 À/À CD8 + T cells primed against irrelevant antigen, or against tumor antigens but transferred into tumor-free mice, did not proliferate ( Figure 2E ; Figure S2F ). Although the presence of Foxp1 abrogated the proliferative capacity of tumor-reactive T cells in vivo, they retain their capacity to produce IL-2 and >20% of them show CD69 expression in vivo ( Figures S2G and S2H) . However, the expression of Foxp1 abolished the effector activity of antitumor lymphocytes after transfer into tumors ( Figure 2F ). Significantly higher numbers of Foxp1-deficient T cells sorted from peritoneal washes after 3 days in the TME reacted by secreting interferon-g (IFN-g) and cytolytic Granzyme-B in recall ELISPOT analysis, compared to identically handled control CD8 + lymphocytes ( Figure 2F ). Importantly, superior effector activity in the absence of Foxp1 was amplified in the TME, compared to mild differences found after in vitro priming ( Figure 2G ). Collectively, these results indicate that the presence of Foxp1 in tumor-reactive T cells is sufficient to prevent their effector activity in the TME upon reencounter with cognate tumor antigens.
Accordingly, the adoptive transfer of tumor antigen-primed T cells lacking Foxp1 dramatically delayed the progression of established and aggressive ID8-Defb29-Vegf-a orthotopic tumors, while identically activated WT T cells only induced modest protection ( Figure 3A) . Notably, a fraction of mice treated with Foxp1-deficient T cells in every independent experiment did not show signs of disease >4 months after tumor challenge. To define whether Foxp1-deficient lymphocytes promoted longterm protection against tumor recurrences, we rechallenged these mice with ID8-Defb29-Vegf-a flank (axillary) tumors. As shown in Figure 3B , all long-term survivors rejected secondary tumors, while all control (naive) mice developed >2 cm tumor masses. As expected, mice with selective ablation of Foxp1 in T cells also exhibited superior outcomes when they were directly challenged with orthotopic tumors ( Figure S3A ).
To define whether the superior antitumor activity of Foxp1-deficient T cells is applicable to non-ovarian malignancies, we generated sarcoma cell lines (termed MPKAS) from tumors resulting from the administration of adenovirus-Cre into the flank of Trp53 f/f LSL-Kras G12D/+ (Trp53-Kras) mice . We pulsed DCs with immunogenic (g-plus UV-irradiated) tumor cells and used them to de novo prime T cells. Again, the growth of MPKAS flank tumors was significantly delayed when Foxp1-deficient tumor-reactive T cells were administered directly into the tumor mass, compared to identically stimulated WT T cells ( Figure 3C ). In addition, intratumoral administration of Foxp1-defective, but not control tumor-reactive T cells, induced massive necrosis in flank tumors that were initiated with adenovirus-Cre in Trp53-Kras mice ( Figure 3D ; Figure S3B ). Together, these results confirm that the expression of Foxp1 is sufficient to abrogate the protective activity of antitumor cytotoxic T cells in the TME and identify an important mechanism of tumor-induced T cell unresponsiveness. mice also allowed their expansion in the presence of TGF-b, while mocked-transduced lymphocytes remained inhibited, despite the robust preactivation required for retroviral transduction ( Figure 4B ; Figures S4B and S4C) .
Next, we aimed to define whether resistance to TGF-b was sufficient to explain the superior antitumor protection elicited by Foxp1-deficient CD8 + T cells. For that purpose, we treated ID8-Defb29-Vegf-a tumor-bearing mice with tumor antigenprimed T cells carrying a dominant-negative TGF-bR type II (dnTGF-bRII), in which TGF-b signaling is blocked (Chen et al., 2005; Gorelik and Flavell, 2000) . As shown in Figure S4D , dnTGF-bRII T cells elicited survival increases higher than those induced by identically primed T cells from WT littermates, despite the fact that Foxp1 was still upregulated in the TME ( Figure S4E ). Correspondingly, MPKAS sarcoma-reactive dnTGF-bRII T cells also elicited superior effects against flank tumor growth, compared to WT lymphocytes (Figure 4C ). Most importantly, combined blockade of CXCL12 signaling and TGF-b resistance prevented the upregulation of Foxp1 in the TME (Figure S4F ), resulting in antitumor effects equivalent to the administration of Foxp1-deficient T cells (Figure 4C ; Figure S4G ). Therefore, although the blatant superiority of Foxp1-deficient T cells is not fully recapitulated by TGFb-resistance alone, these results confirm that TGF-b is nevertheless a major contributor to antitumor T cell unresponsiveness. Therefore, the capacity of Foxp1 À/À lymphocytes to overcome TGF-b-mediated inhibition is relevant for their enhanced activity
Immunity
Foxp1 Drives Immunosuppression in Cancer in the TME, and combined TGF-b and CXCL12 signals cause Foxp1 overexpression in at least some tumors. We then aimed to elucidate the mechanism whereby Foxp1-deficient CD8 + T cells become resistant to TGF-b-mediated inhibition. In the canonical TGF-b pathway, binding of TGF-b to a TGF-bRI and TGF-bRII receptor dimer drives phosphorylation and nuclear translocation of Smad2 and Smad3 molecules, which interact with corepressors to suppress T cell function (Siegel and Massagué , 2003) . We therefore first ruled out repression of either the TGF-bR or downstream Smad2 and Smad3 by Foxp1, at either resting or activated stages ( Figures   5A and 5B). Furthermore, Smad2 and Smad3 phosphorylation occurred as effectively in control T cells as in Foxp1-deficient lymphocytes ( Figures 5B and 5C ). Smad4-dependent nuclear translocation of Smad2 and Smad3 (Siegel and Massagué , 2003) was also unaffected by the absence of Foxp1, as shown by immunofluorescent analysis of Foxp1-deficient CD8 + T cells treated with TGF-b ( Figure 5D ). Collectively, these data indicate that Foxp1 is required for TGF-b-mediated inhibition of tumor-reactive T cells, through a mechanism that takes place downstream of Smad2 and Smad3 translocation, which is sufficient to explain why Foxp1 À/À lymphocytes 
Foxp1 Drives Immunosuppression in Cancer remain responsive in the TME and exert superior antitumor protection.
Foxp1 Is a Component of Smad Nuclear Repression Complex
To define whether Foxp1 interacts with Smad2 and Smad3 proteins in the nucleus after TGF-b-induced translocation, we next performed confocal microscopy analysis of primary human and mouse CD8 + T cells. As shown in Figure 5E , Foxp1 colocalized with Smad2 and Smad3 in the nucleus of T cells after TGF-b signaling. Because in some cell types, Smad2 and Smad3 partner with other transcriptional repressors such as TGIF and CtBP1 (Postigo et al., 2003; Siegel and Massagué , 2003) , we hypothesized that Foxp1 could be a necessary component of the transcriptionally repressive Smad2 and Smad3 complex in CD8 + T cells. To confirm the physical interaction between Smad and Foxp1, we stably cotransfected HeLa cells with Flag-tagged human Foxp1 and hemagglutinin (HA)-tagged human Smad2. Immunoblot analysis confirmed that immunoprecipitates of tagged Smad2 contained a band corresponding to Flag-tagged Foxp1 that was recognized by a-Flag antibodies ( Figure 6A ). Coimmunoprecipitation of Foxp1 and Smad2 was specific because abundant proteins such as b-actin were not pulled down, and immunoprecipitates of irrelevant (a-Lck) Abs did not contain Foxp1 ( Figure 6A ). Correspondingly, reverse (a-Flag Foxp1) immunoprecipitates, but not irrelevant pulldowns, contained interacting Smad2 and Smad3 proteins in independent experiments ( Figure 6B ).
To verify that Smad2 and Foxp1 also interact in primary human T cells, we nucleofected CD3 and CD28 preactivated lymphocytes from the peripheral blood of two different healthy donors with tagged Smad2 and Foxp1. Immunoprecipitation (IP) of Smad2-HA, but not of (irrelevant) Lck, again specifically pulled down Flag-tagged Foxp1 and not b-actin ( Figure 6C ), confirming that Foxp1 physically binds to the Smad2 and Smad3 complex also in primary T cells.
Finally, to confirm the interaction between endogenous Smad2 and Foxp1 in primary lymphocytes, we CD3-and CD28-activated mouse T cell splenocytes (both Foxp1-deficient and control lymphocytes) in the presence of TGF-b and performed new immunoprecipitation analysis. As expected, immunoprecipitates of a-Smad2 and Smad3 Abs (but not irrelevant a-Lck Abs) contained endogenous Foxp1 and not b-actin, and that occurred only when control Foxp1 + T cells were used (Figure 6D ). These results demonstrate that this proposition, we focused on the cell-cycle promoter Myc, a known target of the TGF-b pathway that is transcriptionally repressed through direct binding of Smad to its promoter (Yagi et al., 2002) . As shown in Figure 7A , TGF-b greatly diminished CD3 and CD28-induced c-Myc overexpression in Foxp1 + T cells, whereas it had negligible effects on identically treated Foxp1-deficient CD8 + lymphocytes. As expected, ERK inhibitors abrogated Myc upregulation independently of Foxp1 (Figure S5A) . To determine whether Foxp1 physically associates with the Myc promoter, we performed chromatin immunoprecipitation (ChIP) with specific Abs. As shown in Figure 7B , we observed enrichment of the fragment of the Myc promoter containing a reported Smad binding site (Yagi et al., 2002) in Foxp1-DNA precipitates, compared to control pull-downs with an irrelevant immunoglobulin G (IgG). Supporting the specificity of the binding to the Myc promoter, no enrichment was found for the sequence of a control (MISIIR) promoter, primarily expressed in Mullerian epithelium ( Figure 7B ).
To identify additional Foxp1-dependent mechanisms that explain the superior activity of Foxp1-deficient T cells in the TME, we finally focused on concurrent activation of nuclear factor of activated T cells (NFAT) and AP-1, a coordinated process needed for optimal T cell effector function (Maciá n et al., 2002) . We found that CD3 and CD28-induced NFAT2 upregulation was not affected by TGF-b signaling or the absence of Foxp1 expression ( Figure 7C ). In contrast, the expression of total c-Jun, a crucial component of the AP-1 transcriptional complex in T cells (Chen et al., 1998; Li et al., 2012) , was increased in TGFb-treated Foxp1 À/À T cells, compared to WT lymphocytes (Figure 7D) . Most importantly, c-Jun phosphorylation in CD3 and CD28-activated T cells was decreased upon TGF-b signaling, in a Foxp1-dependent manner ( Figure 7D ). Therefore, Foxp1 is required for TGF-b-induced reduction of the AP-1/NFAT ratio in CD8 + T cells, which is associated with T cell unresponsiveness (Maciá n et al., 2002) . As demonstrated for c-Myc, we observed enrichment of c-Jun promoter sequences in Foxp1-DNA precipitates, suggesting that the TGF-b-induced complex inhibits cJun through transcriptional repression ( Figure 7E ). In addition, enrichment was higher when T cells were activated in the presence of TGF-b ( Figure 7E ). Together, our results indicate that the Foxp1-mediated inhibitory program triggered by TGF-b includes direct transcriptional suppression of at least two important transcription factors required for optimal T cell activation; namely, c-Myc and AP-1. We also found that tumor antigen-primed T cells upregulate Foxp1 after homing to the TME, which is in contrast with sustained Foxp1 downregulation exhibited by exhausted CD8 + lymphocytes in chronic viral infections (Doering et al., 2012) . While multiple inhibitory mechanisms identified in chronic infections also play a role in the suppression of antitumor immunity, solid tumors orchestrate different microenvironments. Our results underscore the importance that these differences, along with specific tolerogenic networks in the TME (Cui et al., 2013; Watkins et al., 2011; Zou, 2005) , and/or the weaker nature of tumor antigen-specific responses (Wang et al., 2006; Zhu et al., 2013) rior antitumor effector functions. Although Foxp1-deficient T cell immunotherapy prolonged survival and protected mice from secondary tumor challenges, we failed to recover adoptively transferred cells from tumor-free mice. Thus, Foxp1-deficient T cells, besides directly targeting tumor cells, might boost host endogenous antitumor immunity The molecular pathways by which Foxp1 impairs the effector activity of TILs demands further investigation, but Smad factors are known to bind to the Granzyme-B and IFN-g promoters (Thomas and Massagué , 2005) . It is therefore likely that Foxp1 also mediates these suppressive effects. Correspondingly, we found that adoptively transferred tumor-reactive Foxp1-deficient T cells are able to induce the regression of aggressive established tumors, without noticeable toxicity. Foxp1-dependent repression therefore emerges as fundamental mechanism of T cell unresponsiveness, different from other transcriptional programs such as anergy or exhaustion. Ablation of Foxp1 in tumor antigen-primed or chimeric receptor antitumor T cells (e.g., through TALEN or CRISPR technologies) could empower lymphocytes to resist immunosuppressive networks in solid tumors, thus allowing more effective clinical interventions.
EXPERIMENTAL PROCEDURES
Mice Female C57BL/6 and congenic CD45.1 + Ly5.2 mice, aged 5-6 weeks were purchased from the Frederick Cancer Research Facility of the National Cancer Institute. Foxp1 f/f and Foxp1 f/f Cd4-Cre mice (Feng et al., 2011) were provided by Hui Hu and backcrossed with C57BL/6 mice for 12 generations. dnTGFbRII mice (Chen et al., 2005; Gorelik and Flavell, 2000) procured from the Jackson Laboratories were used at 6 weeks of age. Trp53-Kras (p53/K-ras) double-transgenic mice in C57BL/5 background were described earlier . All animals were maintained in specific pathogen-free barrier facilities and used in accordance with the institutional animal care and use guidelines of the Wistar Institute. Ovarian and sarcoma tumor-bearing mice were euthanized if they showed ruffled fur, lethargy, anorexia, reluctance to move, ocular discharge, or labored respiration.
T Cell Tumor Antigen Priming T cells tumor-free
control littermates mice were primed with tumor antigen-pulsed bone-marrow dendritic cells (BMDCs) as described ) with slight variations. Briefly, day six BMDCs were pulsed overnight with g-irradiated (10,000 rad) and UV-treated (30 min) ID8-Defb29-Vegf-a, MPKAS tumor cells or NIH 3T3 fibroblasts at a 10:1 (DC:tumor cell) ratio. For Trp53-Kras flank tumors, DCs were primed with lysates from advanced dissociated tumors subjected to nine quick freeze and thaw cycles. Tumor antigen-pulsed BMDCs were cocultured with Foxp1-deficient or WT T cells at a 1:10 (DC to T cell) ratio in the presence of IL-2 (10 U/ml) and IL-7 (1 ng/ml) (both from Peprotech) for 7 days. Antigen-primed T cells on day 7 were either analyzed immediately (following Cell Trace Violet labeling in some experiments) or transferred into congenic autologous tumor-bearing or tumor-free mice.
Tumor Induction and T Cell Immunotherapy ID8-Defb29-Vegf-a ovarian tumors were induced in CD45.1 + congenic female mice as reported previously Nesbeth et al., 2009 ). Briefly, 2 3 10 6 ID8-Defb29-Vegf-a tumor cells were injected intraperitoneally.
Tumor-bearing mice received 2 3 10 6 antigen primed T cells intraperitoneally on day 24 posttumor challenge and were evaluated for disease progression and survival. ID8-Defb29-Vegf-a flank tumors were induced by subcutaneous injection of 2 3 10 6 tumor cells in the axilla. MPKAS sarcomas were induced by injecting 1 3 10 5 tumor cells subcutaneously in the flank of 6-to 8-week-old male mice. To induce flank tumors in Trp53-Kras transgenic mice, we subcutaneously injected 10 8 pfu adenovirus-expressing Cre (Gene Transfer Vector
Core, University of Iowa) into the dorsolateral flank. Tumor antigen-primed T cells were intratumorally injected into palpable tumors three times (once per week), followed by measuring of tumor growth. give approximately 80 bp amplicons). Results shown for each ChIP condition were analyzed in two ways: By using the percent input method, the amount of DNA recovered from the ChIP were divided by signals obtained from the input sample (signals calculated with 2.5% of the amount of chromatin used in the ChIP). By using the fold enrichment method, the ChIP signals were divided by the irrelevant antibody signals, representing the ChIP signal as the fold increase in signal relative to the background signal.
Statistical Analysis
Mann-Whitney U tests were used for calculating differences between means of experimental groups, and the log rank test was used when analyzing survival experiments. All statistical analysis was performed with GraphPad Prism 5.0 software. A p value of less than 0.05 was considered statistically significant.
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